Abstract: Cisplatin derivatives can form various types of DNA lesions (DNA-Pt) and trigger pleiotropic DNAd amage responses.H ere,w er eport as trategy to visualize DNA-Pt with high resolution, taking advantage of an ovel azidecontaining derivative of cisplatin we named APPA, ac ellular pre-extraction protocol and the labeling of DNA-Pt by means of click chemistry in cells.O ur investigation revealed that pretreating cells with the histone deacetylase (HDAC)inhibitor SAHA led to detectable clusters of DNA-Pt that colocalized with the ubiquitin ligase RAD18 and the replication protein PCNA. Consistent with activation of translesion synthesis (TLS) under these conditions,SAHA and cisplatin cotreatment promoted focal accumulation of the low-fidelity polymerase Polh that also colocalized with PCNA. Remarkably,t hese cotreatments synergistically triggered mono-ubiquitination of PCNAa nd apoptosis in aR AD18-dependent manner.O ur data provide evidence for ar ole of chromatin in regulating genome targeting with cisplatin derivatives and associated cellular responses.
Emerging evidence indicates that functional interactions between small molecules and genomic DNAa re influenced by chromatin features. [1, 2] Cisplatin derivatives represent some of the most commonly employed drugs in the clinical management of cancer. [3] These drugs form covalent bonds with purine residues to produce toxic DNA-Pt including mono-adducts,i nter-a nd intra-strand crosslinks.T hus,c ellular responses to cisplatin are pleiotropic and inherently complex. Fore xample,d iverse repair mechanisms including nucleotide excision repair (NER), base excision repair (BER) and DNAc rosslink repair involving the Fanconi anemia pathway can process DNA-Pt, and these lesions can also alter the structure of chromatin or be influenced by chromatin features. [4] Alternatively,l ow-fidelity DNAp olymerases (e.g. Polh)c an bypass DNA-Pt through am echanism known as translesion synthesis,e nabling continued replication in the presence of DNA-Pt, conferring resistance to platinum (Pt) drugs. [5] To study DNA-Pt in the context of chromatin, we sought to develop as urrogate probe that would allow for the chemical labeling of DNA-Pt in cells.V isual detection of DNA-Pt with high resolution at the single-cell level can potentially provide the means to monitor proteins at sites of lesions and to identify small molecules with ap ropensity to modulate targeting with cisplatin derivatives in an unbiased manner.P rior expertise in characterizing mechanisms of action of small molecules prompted us to develop an azidecontaining derivative to label DNA-Pt by means of click chemistry. [1, 6] Previous efforts towards the synthesis of clickable cisplatin derivatives suitable for cell imaging led to the development of an iminoacridine-Pt complex and af lexible alkyl-azide-containing derivative. [7] With this in mind, we synthesized the cyclic azidoplatinum-containing derivative we named 2-aminomethylpyridine (dichloro) Pt II azide (APPA, Figure 1A and Supporting Information). [8] Thed esign of APPAw as inspired from the structures of cisplatin and picoplatin ( Figure 1A ), taking advantage of the aromatic methyl substituent to form arigid five-membered ring with Pt. Thus,APPAexhibits astructure that can form bulky DNAl esions,w here the ring prevents free rotation of the pyridine core chelated to Pt. This structural distinction was considered important given that the chemical nature of ligands bound to Pt at sites of lesions in cells can potentially affect how these lesions are detected and dealt with. [9] Like cisplatin and picoplatin, APPAe xhibited anti-proliferative properties against human osteosarcoma U2OS cells ( Figure 1B) . Thus,w ee valuated the reactivity of APPAtowards DNAand our ability to label DNA-Pt with strained or terminal alkyne-containing fluorophores.A26-mer hairpin-forming DNAo ligonucleotide containing as ingle 1,2-GG dinucleotide,p rone to form an intra-strand crosslink upon treatment with Pt drugs,w as incubated with APPA, purified and then incubated with as trained alkynecontaining Alexa 488 ( Figure 1C) . [10] Ther eaction products were then analyzed and characterized by mass spectrometry. We identified three ion peaks corresponding to the free unreacted hairpin along with the unlabeled and fluorescently labeled Pt adducts ( Figure 1D ). Next, we performed similar experiments in cells using APPAand the control compound 2-aminomethylpyridine (dichloro) Pt Figure 1E ). This data demonstrated that APPAc an form DNA-Pt with genomic DNAinl iving cells.
With this methodology in hand, we investigated the localization of DNA-Pt in cells.T othis end, cells were treated with APPAa nd fixed with formaldehyde prior to labeling DNA-Pt using copper catalysis.C onsistent with previous observations, [7, 11] labeled DNA-Pt exhibited ad iffuse cytoplasmic and nuclear staining (Figure 2A ), which likely reflected the targeting of nuclear DNAa sw ell as proteins and RNA. As am eans to selectively detect DNA-Pt, we implemented apre-extraction protocol to remove the staining linked to soluble proteins and RNAt argets of Pt drugs ( Figure 2B ). This protocol allowed for the detection of labeled DNA-Pt in the nucleus with some sub-nuclear regions displaying increased fluorescence intensity ( Figure 2C ). For instance,l abeled DNA-Pt colocalized with fibrillarin (see Supporting Information), in agreement with the idea that Pt drugs target rRNAinthe nucleolus.
[7b] Collectively,these data validated APPAa safunctional clickable probe suitable for studying genome targeting with cisplatin derivatives in cells.
Next, we searched for small molecule modulators of genomic DNAt argeting with cisplatin derivatives,u sing APPAs taining as ar eadout. We screened ad efined set of small molecules that either operate at the level of chromatin or that are used in cancer treatment in conjunction with Pt drugs ( Figure 3A and Supporting Information). U2OS cells were cotreated independently with each small molecule and APPA, then subjected to chemical labeling and labeled DNAPt were analyzed by fluorescence microscopy.W hile most small molecules had no discernable effect on the localization of DNA-Pt, pre-treatment with the clinically approved DNA methyl transferase inhibitor azacytidine (5-Aza) [12] and the histone deacetylase (HDAC)i nhibitor SAHA [13] led to the occurrence of foci of DNA-Pt, indicating the presence of targeted clusters of purine residues at these sites that can include mono-adducts,1 ,2-GG and 1,3-GTG intra-strand as well as inter-strand lesions ( Figure 3B and C) . Western blotting analysis confirmed that SAHA induced hyperacety- lation of histone H4 (see Supporting Information), an established marker of open chromatin. [14] Furthermore,t he structurally distinct Class IH DACi nhibitor MS-275 [15] also led to increased number of DNA-Pt foci, implicating further the role of HDACsa nd chromatin in genome targeting with APPA( see Supporting Information). Importantly,t he intensity of DNA-Pt foci was reduced when cells were cotreated with at wo-fold excess of cisplatin acting as ac ompetitor, indicating that both APPAa nd cisplatin target similar genomic loci ( Figure 3D ). These data suggested that chromatin relaxation resulting from SAHA treatment revealed de novo DNAtargets of APPA. Interestingly, DNA-Pt occurring in SAHA-treated cells did not predominantly colocalize with the centromere and telomere markers CENPAand TRF1, respectively,excluding these loci-containing repetitive sequences rich in 1,2-purine residues as primary targets of APPAu nder these conditions (see Supporting Information).
Given that DNA-Pt can alter transcription, [16] we performed RNA-Seq analyses to evaluate whether SAHA treatment affected the transcriptional response induced by APPA. Our analysis identified as ubset of genes that were up-or downregulated by APPAc ompared to untreated cells ( Figure 3E and Supporting Information). Interestingly,t he transcriptional changes measured in cells cotreated with SAHA and APPAc ould be attributed to that observed either in SAHA or APPAi ndependent treatments.T his supported the idea that the DNA-Pt clusters detected in cotreated cells did not trigger additional transcriptional effects that were unique to this cotreatment. Furthermore, qPCR experiments validated that cisplatin induced similar changes in gene expression compared to APPA, providing further evidence that APPAa nd cisplatin shared genomic targets (see the Supporting Information).
Then, we developed ap rotocol to isolate DNAt argets of APPAf rom cells ( Figure 3F ). Cells were treated with APPA AE SAHA prior to being subjected to affinity pull-down as previously performed for other classes of molecules. [2, 17] Thea mount of DNAp ulled down from cells was similar in both experimental conditions ( Figure 3G ). This result was in line with the idea that SAHA did not solely act by increasing the number of DNAt argets per se,b ut rather induced ar edistribution of DNA-Pt throughout the genome,p otentiating DNAt argeting at particular sites.This was consistent with the idea that chromatin relaxation induced by SAHA altered accessibility of the genome to APPA, providing additional insights into how HDAC inhibitors can sensitize cells to genotoxic drugs. [18] Theo ccurrence of DNA-Pt foci in SAHA-treated cells prompted us to determine whether clusters of lesions could act as physical roadblocks,p otentially affecting DNA-templated processes.S trikingly,D NA-Pt colocalized with RAD18, an E3 ubiquitin ligase that mediates mono-ubiquitination of the proliferating cell nuclear antigen PCNAincells cotreated with SAHA and APPA( Figure 4A ). Moreover, clusters of DNA-Pt also colocalized with PCNA( see Sup- Genes were selected based on differential expression in SAHA and APPA cotreatment compared to untreated. Data from two independentexperiments per condition are shown. Gene expression was monitored by RNA-Seq as described in SupportingInformation.F )Scheme of DNA-Pt pull-downm ethodology.G )Quantification of DNA isolated by pull-down from samples treated as indicated; n = 3. All experiments performed in U2OS cells. Cells were treated with APPA (250 mm for 3h), APP (250 mm for 3h), SAHA (2.5 mm for 5h)and cisplatin (500 mm for 5h). Error bars represent mean AE SD; ***P < 0.001, Student's t-test;NS, not significant.
porting Information). Cotreatment with SAHA and APPA led to mono-ubiquitination of PCNA( Figure 4B ), am ark that can promote the recruitment of low-fidelity polymerases involved in TLS, [19] and cells cotreated with SAHA and cisplatin or APPAe xhibited increased number of RAD18 foci (see Supporting Information). Furthermore,t reatment with SAHA and cisplatin led to the focal accumulation of the TLS polymerase Polh [20] that colocalized with PCNA ( Figure 4C and Supporting Information). Altogether,t hese data were consistent with the notion that SAHA and cisplatin derivatives synergistically activated TLS.Itisnoteworthy that levels of phosphorylated replication protein A( p-RPA) and CHK1 (p-CHK1) were similar in APPA-treated and cotreated cells indicating the absence of additional replication stress (see Supporting Information). This was in agreement with the notion that HDAC inhibitors promoted ar edistribution of DNA-Pt in contrast to aglobal increase in number of lesions.R emarkably,c otreatment with SAHA and APPA triggered apoptosis signaling as defined by the cleavage of PA RP and the activation of caspase 3, in several cancer cell lines including colon carcinoma HCT-116, osteosarcoma U2OS and ovarian carcinoma A2780 cells ( Figure 4D and Supporting Information). To evaluate whether RAD18 was directly involved in apoptotic signaling under these conditions,weperformed similar experiments with matched HCT-116 RAD18 knockout (KO) cells.W estern blotting indicated that cells devoid of RAD18 did not display PCNAm onoubiquitination in response to SAHA and APPAcotreatment ( Figure 4D ). Additionally,m arkers of apoptosis were not detected in HCT-116 RAD18 KO cells even though DNA-Pt foci formed similarly in WT and RAD18 KO cells cotreated with SAHA and APPA( Figure 4D and Supporting Information). These results,along with the RAD18-dependent PCNA mono-ubiquitination implicated RAD18 in promoting apoptosis signaling in response to SAHA and APPAcotreatment. Comparable results were observed in SAHA and cisplatin cotreated WT and RAD18 KO cells,d emonstrating that this response was acommon feature of these cisplatin derivatives ( Figure 4E ). Although the induction of apoptosis signaling by RAD18 could be potentially counterintuitive owing to the well-established role of this factor in DNAr epair processes and TLS, [5] HDAC inhibitors have been shown to re-sensitize cancer cells refractory to cisplatin.
[18] Therefore,o ur results suggested that the higher level of apoptosis signaling observed in RAD18 expressing cells in response to SAHA and cisplatin derivatives is due to the inability of polymerases to efficiently bypass DNA-Pt clusters.F or instance,i ti s possible that chromatin relaxation mediated by SAHA favored the formation of 1,3-GTG intra-strand lesions, which have previously been shown to block TLS polymerases. [21] It is also conceivable that HDAC inhibition promoted lesion bypass at the expense of DNAr epair, [22] thereby leading to detectable clusters of DNA-Pt prone to trigger apoptosis through other mechanisms.
Engagement of the replication machinery with DNA-Pt can promote DNAbreaks and cell death. However,cells can employ DNAd amage tolerance pathways involving monoubiquitinated PCNAand specialized low-fidelity polymerases to bypass DNA-Pt. [5, 23] These processes play ac ritical role in resistance to Pt drugs. [24] To overcome these mechanisms, cisplatin derivatives containing bulkier ligands,o rc ombination therapies with other drugs have been identified. [25] Here, we have developed aversatile strategy to visualize DNA-Pt in cells with high resolution. This methodology has allowed the unbiased identification of small molecule modulators of genome targeting with cisplatin derivatives.I nparticular, we have discovered that treating cells with the HDAC inhibitor SAHA and APPAresulted in detectable clusters of DNA-Pt and activation of aD NA damage response at these sites. While we cannot rule out aputative role of template switching and homologous recombination that could also be mediated by RAD18, the increase of Polh foci in cells cotreated with SAHA and cisplatin is consistent with activation of TLS. Thus,t he response observed in these conditions comes in agreement with reports showing that clustered DNAl esions can impair DNAdamage response pathways. [26] This study has uncovered unanticipated insights into how chromatin alterations can affect the targeting of genomic DNAa nd sensitization of cancer cells to cisplatin derivatives,establishing arobust experimental platform for basic and translational research relying on chromatin-targeting small molecules. [27] 
